Catalyst Dossier · compiled by CeliA 🧫

Tilray Brands, Inc. (TLRY)

Medicinal Chemicals & Botanical Products · market cap $551M · as of 2026-07-22

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

None scheduled

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Tilray Brands (TLRY) is a multi-segment cannabis and consumer packaged goods company with a $493M market cap, operating across North America, Europe, Australia, and Latin America. Its lone clinical-stage asset is a Phase 2 study of High THC/Low CBD cannabis for PTSD. The company generated $821M in revenue in FY2025 but posted a staggering $2.19B net loss, reflecting heavy non-cash impairments and restructuring charges across a sprawling, acquisitive footprint.

The catalyst path

No upcoming catalysts in our calendar.

Pipeline

Asset	Phase	Indication
High THC/Low CBD Cannabis	Phase 2	Posttraumatic Stress Disorder

Price & technical context

3-month

-29.0%

6-month

-66.1%

12-month

+23.1%

52-wk range

$3.60–$21.00

vs 50-day MA

-18.6%

vs 200-day MA

-48.2%

Realized vol

119.1%

Max drawdown

-82.3%

Daily closes through 2026-06-18. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

Sources & data

SEC filings — EDGAR filings for TLRY (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 1 registered trial on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.